Kristopher Croome, Roberto Hernandez‐Alejandro – 31 January 2014

Mi‐Jung Jun, Ju Hyun Shim, So Yeon Kim, Nieun Seo, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Eunsil Yu, Sung‐Gyu Lee – 30 January 2014 – The role of liver biopsy in selecting optimal donors is an area of continuing controversy in living donor liver transplantation (LDLT). Our aim was to assess the potential implications of preoperative and intraoperative biopsies for evaluating donor liver fat content.

Ping Wan, Xin Yu, Qiang Xia – 30 January 2014 – Living donor liver transplantation (LDLT) has emerged as an alternative to deceased donor liver transplantation (DDLT) because of the increasing number of patients waiting for liver transplantation (LT). However, whether it can achieve operative outcomes similar to those achieved with DDLT for adult patients remains controversial. We conducted this meta‐analysis to compare the operative outcomes of LDLT and DDLT recipients.

Shoji Kubo, Shinji Uemoto, Hiroyuki Furukawa, Koji Umeshita, Daisuke Tachibana, for the Japanese Liver Transplantation Society – 30 January 2014 – A national survey of pregnancy outcomes after living donor liver transplantation (LDLT) was performed in Japan. Thirty‐eight pregnancies in 30 recipients resulted in 31 live births (25 recipients), 3 artificial abortions in the first trimester (3 recipients), 1 spontaneous abortion (1 recipient), and 3 fetal deaths (3 recipients).

Nick Schofield, Anita Sugavanam, Karen Thompson, Susan V. Mallett – 30 January 2014 – The aims of this study were to determine whether the withdrawal of aprotinin (APRO) led to an increased bleeding risk in patients undergoing orthotopic liver transplantation (OLT). A retrospective analysis compared consecutive patients undergoing OLT and treated with aprotinin (APRO group; n = 100) with a group in which aprotinin was not used (no‐APRO group; n = 100). Propensity score matching was then performed for each group to identify 2 matched cohorts.

Hynek Mergental, Firas Zahr Eldeen, Paolo Muiesan, Darius Mirza – 30 January 2014

Katharine Secunda, Josh Levitsky – 30 January 2014

David A. Axelrod, Krista L. Lentine, Huiling Xiao, Nino Dzebisashvilli, Mark Schnitzler, Janet E. Tuttle‐Newhall, Dorry L. Segev – 30 January 2014 – Despite improved overall liver transplant outcomes, biliary complications remain a significant cause of morbidity. A national data set linking transplant registry and Medicare claims data for 17,012 liver transplant recipients was used to identify all recipients with a posttransplant biliary diagnosis code within the first 6 months after transplantation.

Enke Grabhorn, Konstantinos Tsiakas, Uta Herden, Lutz Fischer, Peter Freisinger, Thorsten Marquardt, Rainer Ganschow, Andrea Briem‐Richter, René Santer – 30 January 2014 – Deoxyguanosine kinase (DGUOK) deficiency is a well‐known cause of hepatocerebral mitochondrial DNA depletion syndromes, which include a broad spectrum of clinical presentations. Affected patients often develop life‐threatening liver failure, but the benefits of liver transplantation (LT) are controversial because of the frequently severe neurological involvement due to the underlying mitochondrial disease.

Yongin Cho, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Dong Jin Joo, Myoung Soo Kim, Bong Soo Cha, Joong‐Yeol Park, Eun Seok Kang – 30 January 2014 – New‐onset diabetes after transplantation (NODAT) and dyslipidemia are important metabolic complications after liver transplantation (LT) that can adversely affect both allograft and patient survival. Statins are used as first‐line therapies for dyslipidemia because of their effectiveness and safety profile. However, it has recently been reported that statin therapy is associated with new‐onset diabetes in the nontransplant population.